Alnylam Pharmaceuticals | ALNY - Assets

Stock Price
327.18
Daily Change
-5.67 -1.70%
Monthly
-9.46%
Yearly
33.43%
Q1 Forecast
325.77

Alnylam Pharmaceuticals reported $4.97B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
Acadia Pharmaceuticals USD 1.33B 105.22M Sep/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
BioCryst Pharmaceuticals USD 446.42M 10.76M Sep/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Moderna USD 12.34B 203M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Novartis USD 107.29B 2.89B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 126.81B 25.48B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Takeda JPY 15.41T 938.47B Dec/2025
Tectonic Therapeutic USD 277M 18.31M Sep/2025
Ultragenyx Pharmaceutical USD 1.53B 341.56M Dec/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025
Xencor USD 868.81M 10.61M Sep/2025